{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:48:55Z","timestamp":1778089735567,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.slasd.2024.100186","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:35:02Z","timestamp":1727825702000},"page":"100186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor"],"prefix":"10.1016","volume":"29","author":[{"given":"Thomas S.","family":"Dexheimer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan P.","family":"Coussens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Silvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Moscow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly A.","family":"Teicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2024.100186_bib0001","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acs.chemrestox.9b00476","article-title":"The Ah receptor: adaptive metabolism, ligand diversity, and the xenokine model","volume":"33","author":"Avilla","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.slasd.2024.100186_bib0002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.pharmtox.40.1.519","article-title":"The PAS superfamily: sensors of environmental and developmental signals","volume":"40","author":"Gu","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.slasd.2024.100186_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.pharmtox.43.100901.135828","article-title":"Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals","volume":"43","author":"Denison","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.slasd.2024.100186_bib0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/138920011795016818","article-title":"Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art","volume":"12","author":"Stejskalova","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.slasd.2024.100186_bib0005","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1515\/bc.2010.128","article-title":"An introduction to the molecular basics of aryl hydrocarbon receptor biology","volume":"391","author":"Abel","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.slasd.2024.100186_bib0006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.drudis.2012.11.014","article-title":"The AhR twist: ligand-dependent AhR signaling and pharmaco-toxicological implications","volume":"18","author":"Guyot","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.slasd.2024.100186_bib0007","doi-asserted-by":"crossref","first-page":"16625","DOI":"10.1038\/s41598-022-20572-2","article-title":"AHR is a master regulator of diverse pathways in endogenous metabolism","volume":"12","author":"Granados","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2024.100186_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114845","article-title":"An overview of aryl hydrocarbon receptor ligands in the last two decades (2002-2022): a medicinal chemistry perspective","volume":"244","author":"Lin","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.slasd.2024.100186_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186654","article-title":"Aryl hydrocarbon receptor (AHR) ligands as selective AHR modulators (SAhRMs)","volume":"21","author":"Safe","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2024.100186_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225574","article-title":"The role of the aryl hydrocarbon receptor (AhR) and its ligands in breast cancer","volume":"14","author":"Safe","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.slasd.2024.100186_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010387","article-title":"How the AHR became important in cancer: the role of chronically active AHR in cancer aggression","volume":"22","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2024.100186_bib0012","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3846","article-title":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","volume":"14","author":"Murray","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.slasd.2024.100186_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123851","article-title":"The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases","volume":"19","author":"Neavin","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2024.100186_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020752","article-title":"AhR and cancer: from gene profiling to targeted therapy","volume":"22","author":"Paris","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2024.100186_bib0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2024.100186_bib0016","doi-asserted-by":"crossref","first-page":"15422","DOI":"10.1016\/S0021-9258(18)47743-5","article-title":"Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances","volume":"262","author":"Rannug","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.slasd.2024.100186_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173921","article-title":"The footprint of kynurenine pathway in every cancer: a new target for chemotherapy","volume":"896","author":"Ala","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.slasd.2024.100186_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the immune response by the aryl hydrocarbon receptor","volume":"48","author":"Gutierrez-Vazquez","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.slasd.2024.100186_bib0019","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.it.2018.10.010","article-title":"The aryl hydrocarbon receptor: connecting immunity to the microenvironment","volume":"39","author":"Shinde","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.slasd.2024.100186_bib0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities","volume":"39","author":"Cheong","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.slasd.2024.100186_bib0021","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.slasd.2024.100186_bib0022","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cotox.2017.01.012","article-title":"The Aryl Hydrocarbon Receptor (AhR) as a Drug Target for Cancer Chemotherapy","volume":"2","author":"Safe","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.slasd.2024.100186_bib0023","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00204-017-1981-2","article-title":"Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target","volume":"91","author":"Kolluri","year":"2017","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.slasd.2024.100186_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807271","article-title":"Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives","volume":"13","author":"Peyraud","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.slasd.2024.100186_bib0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fonc.2018.00423","article-title":"Updates in the clinical development of epacadostat and other indoleamine 2,3-dioxygenase 1 inhibitors (IDO1) for human cancers","volume":"8","author":"Komiya","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.slasd.2024.100186_bib0026","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.slasd.2024.100186_bib0027","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase i results from a multicenter, open-label phase I\/II Trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2024.100186_bib0028","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.slasd.2024.100186_bib0029","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1039\/D1MD00015B","article-title":"Recent advances in the development of AHR antagonists in immuno-oncology","volume":"12","author":"Sun","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.slasd.2024.100186_bib0030","unstructured":"Bayer. A first-in-humans dose finding study for an aryl hydrocarbon receptor inhibitor (AhRi) in patients with advanced cancer. https:\/\/classic.clinicaltrials.gov\/show\/NCT04069026; 2019."},{"key":"10.1016\/j.slasd.2024.100186_bib0031","unstructured":"Bayer. A study to learn how safe the study drug BAY 2416964 (AhR Inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults. https:\/\/classic.clinicaltrials.gov\/show\/NCT04999202; 2021."},{"key":"10.1016\/j.slasd.2024.100186_bib0032","unstructured":"Oncology I., Squibb B.M. A phase 1a\/b study of ik-175 as a single agent and in combination with nivolumab in patients with locally advanced or Metastatic solid tumors and urothelial Carcinoma. https:\/\/classic.clinicaltrials.gov\/show\/NCT04200963; 2019."},{"key":"10.1016\/j.slasd.2024.100186_bib0033","unstructured":"Oncology I., Squibb B.M. Oral AHR antagonist in combination with nivolumab in patients with PD-1 resistant metastatic or recurrent head and neck cancer. https:\/\/classic.clinicaltrials.gov\/show\/NCT05472506; 2022."},{"key":"10.1016\/j.slasd.2024.100186_bib0034","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/bph.12576","article-title":"In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract","volume":"171","author":"Fang","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.slasd.2024.100186_bib0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.110.178392","article-title":"Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism","volume":"338","author":"Smith","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.slasd.2024.100186_bib0036","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1124\/mol.105.021832","article-title":"Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor","volume":"69","author":"Kim","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.slasd.2024.100186_bib0037","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1177\/24725552211038362","article-title":"Complex tumor spheroids, a tissue-mimicking tumor model, for drug discovery and precision medicine","volume":"26","author":"Kaur","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2024.100186_bib0038","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/2767-9764.CRC-23-0193","article-title":"Multicellular complex tumor spheroid response to DNA repair inhibitors in combination with DNA-damaging drugs","volume":"3","author":"Dexheimer","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.slasd.2024.100186_bib0039","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-23-0267","article-title":"Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource","author":"Morris","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.slasd.2024.100186_bib0040","first-page":"285","article-title":"Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches","volume":"11","author":"Hamilton","year":"1984","journal-title":"Semin Oncol"},{"key":"10.1016\/j.slasd.2024.100186_bib0041","first-page":"7","article-title":"Pharmacologic reversal of drug resistance in ovarian cancer","volume":"12","author":"Ozols","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1016\/j.slasd.2024.100186_bib0042","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-021-02936-w","article-title":"TPM, FPKM, or normalized counts? A comparative study of quantification measures for the analysis of RNA-seq data from the NCI patient-derived models repository","volume":"19","author":"Zhao","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.slasd.2024.100186_bib0043","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.slasd.2024.100186_bib0044","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nm.4474","article-title":"A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment","volume":"24","author":"Hyer","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.slasd.2024.100186_bib0045","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2024.100186_bib0046","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bcp.2005.12.038","article-title":"Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists","volume":"71","author":"Negus","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.slasd.2024.100186_bib0047","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/1541-7786.MCR-12-0216","article-title":"Ah receptor antagonism represses head and neck tumor cell aggressive phenotype","volume":"10","author":"DiNatale","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.slasd.2024.100186_bib0048","unstructured":"Gutcher I., R\u00f6hn U., Schmees N., Zorn L., R\u00f6se L., Bader B., et al. 2-Heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer. U.S. Patent Application 17\/819, 602; 2023."},{"key":"10.1016\/j.slasd.2024.100186_bib0049","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.str.2017.05.001","article-title":"Dissecting the specificity of adenosyl sulfamate inhibitors targeting the ubiquitin-activating enzyme","volume":"25","author":"Misra","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.slasd.2024.100186_bib0050","doi-asserted-by":"crossref","first-page":"40867","DOI":"10.1074\/jbc.M111.279984","article-title":"Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.slasd.2024.100186_bib0051","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ","volume":"37","author":"Brownell","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.slasd.2024.100186_bib0052","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/mol.110.065078","article-title":"Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"78","author":"Tan","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.slasd.2024.100186_bib0053","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bcp.2010.08.016","article-title":"A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP\/ABCG2 in LS174T cells","volume":"80","author":"Tompkins","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.slasd.2024.100186_bib0054","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141518","article-title":"A genome-wide CRISPR\/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity","volume":"6","author":"Barghout","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.slasd.2024.100186_bib0055","article-title":"Overexpression of ABCG2 confers resistance to MLN7243, a ubiquitin-activating enzyme (UAE) inhibitor","volume":"9","author":"Wu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.slasd.2024.100186_bib0056","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1021\/acschembio.2c00451","article-title":"Combinatorial anticancer drug screen identifies off-target effects of epigenetic chemical probes","volume":"17","author":"Barghout","year":"2022","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.slasd.2024.100186_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111858","article-title":"Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor","volume":"388","author":"Wei","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.slasd.2024.100186_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020429","article-title":"ABCG2 overexpression contributes to pevonedistat resistance","volume":"12","author":"Kathawala","year":"2020","journal-title":"Cancers"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555224000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555224000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:14:34Z","timestamp":1744881274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555224000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2472555224000480"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2024.100186","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2024.100186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100186"}}